Internal Dosimetry and Quantification Patents: Leaders, Filing Trends and Open Claim Space
Concentrated at the top. The five leading assignees hold 391 of 1,156 records in scope (33.8%), and the ranked leaders extend to 100 companies with a long tail below the top ten. Filings peaked at 130 in 2017 and had fallen to 53 by 2024, a decline the evidence puts at 46% across the 2021-2024 window (98 to 53). This reads as a maturing claim landscape around the core calibration and correction methods rather than a shrinking field: incumbents who staked out the foundational quantification methods early have less need to keep filing at the same rate, while activity below the surface may still be building toward a next wave once current applications publish.
- 1CORNELL UNIVERSITY94
- 2SLOAN KETTERING INST FOR CANCER RES89
- 3MEMORIAL SLOAN KETTERING CANCER CENT75
- 4ELUCID BIOIMAGING INC69
- 5LANTHEUS MEDICAL IMAGING INC64
See the full internal dosimetry and quantification analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in internal dosimetry and quantitative imaging?
The assignee ranking for this dataset covers 100 companies, with the leading assignee holding 94 of the 1,156 records in scope. The top five combined account for 391 records (33.8% of the field), and the top ten reach 614 records (53.1%). Beyond tenth place, holdings drop off quickly into a long tail of single- and few-filing entrants, so most of the enforceable claim density sits with a small group of academic medical centres and imaging or radiopharmaceutical companies.
Is patent filing in internal dosimetry increasing or declining?
Filings peaked at 130 in 2017 and have declined since, falling from 98 in 2021 to 53 in 2024 — a 46% drop over that span. However, publication typically lags filing by around 18 months, so the lower counts shown for 2025 and 2026 in most trend charts are incomplete rather than evidence of a further slowdown. The safest reading is that the field cooled from its 2017 peak but the 2025-2026 numbers should not yet be trusted as a continuing trend.
What technology areas dominate internal dosimetry patents?
Medicinal preparations under IPC class A61K lead, covering 37.8% of the 1,156 records in scope, followed by A61B diagnosis and surgery methods at 28.5% and G06T image data processing at 21.9%. Because a single patent record can carry multiple IPC classes, these shares add up to well over 100%. The pattern shows that claim activity is weighted toward the radiopharmaceutical agent and the diagnostic method as much as toward the image-processing algorithms that quantify it.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Internal Dosimetry and Quantification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.